We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
Read MoreHide Full Article
On Jul 2, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX - Free Report) . The company’s robust worldwide commercial capabilities and best-in-class products, including the next-generation chemistry analyzer, Catalyst One, are key growth drivers for the days to come. The stock carries a Zacks Rank #3 (Hold), at present.
Over the past three months, this leading molecular diagnostic company has outperformed its industry. The stock has gained 26.4% compared with 5.1% rise of the industry.
IDEXX’s first-quarter 2020 organic revenue growth was encouraging. The top line was driven by strong sales at the CAG business. The company witnessed sturdy gains in Diagnostics recurring revenues, supported by double-digit organic gains in both U.S. and international markets in the quarter under review. In terms of COVID-19-related progress, the company’s SARS-CoV-2 (COVID-19) RealPCR Test for pets in response to customer demand buoys optimism.
Further, the company’s human health business, OPTI Medical Systems, developed a PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR. The company has applied for FDA’s Emergency Use Authorization (EUA) for the same for the detection of SARS-CoV-2.
While the economy has been hit hard by the coronavirus pandemic, IDEXX benefited from it. The company’s Water segment recorded 13% year-over-year growth (up 15% organically), while the Livestock, Poultry and Dairy (LPD) segment recorded 8% year-over-year growth (up 12% organically), both resulting from favorable order timings. This includes accelerated customer stocking orders related to the COVID-19 pandemic.
Of late, IDEXX has been steadily expanding the test menu with CAG. A notable launch of recent times includes Catalyst Bile Acids test along with latest updates to its SediVue Neural Network 5.0.
However, economic stagnation due to the coronavirus outbreak is concerning. Meanwhile, the majority of IDEXX’s consolidated revenues is derived from the sale of products in international markets. Thus, the strengthening of the U.S. dollar’s exchange rate, relative to other currencies, left a negative impact on revenues derived in currencies other than the U.S. dollar as well as on profits drawn from products manufactured in the United States and sold internationally.
Key Picks
Some better-ranked stocks from the broader medical space are Quest Diagnostics Incorporated (DGX - Free Report) , Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp and QIAGEN N.V. (QGEN - Free Report) .
LabCorp’s long-term earnings growth rate is estimated at 6.1%. The company presently has a Zacks Rank #2 (Buy).
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
On Jul 2, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX - Free Report) . The company’s robust worldwide commercial capabilities and best-in-class products, including the next-generation chemistry analyzer, Catalyst One, are key growth drivers for the days to come. The stock carries a Zacks Rank #3 (Hold), at present.
Over the past three months, this leading molecular diagnostic company has outperformed its industry. The stock has gained 26.4% compared with 5.1% rise of the industry.
IDEXX’s first-quarter 2020 organic revenue growth was encouraging. The top line was driven by strong sales at the CAG business. The company witnessed sturdy gains in Diagnostics recurring revenues, supported by double-digit organic gains in both U.S. and international markets in the quarter under review. In terms of COVID-19-related progress, the company’s SARS-CoV-2 (COVID-19) RealPCR Test for pets in response to customer demand buoys optimism.
Further, the company’s human health business, OPTI Medical Systems, developed a PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR. The company has applied for FDA’s Emergency Use Authorization (EUA) for the same for the detection of SARS-CoV-2.
IDEXX Laboratories, Inc. Price
IDEXX Laboratories, Inc. price | IDEXX Laboratories, Inc. Quote
While the economy has been hit hard by the coronavirus pandemic, IDEXX benefited from it. The company’s Water segment recorded 13% year-over-year growth (up 15% organically), while the Livestock, Poultry and Dairy (LPD) segment recorded 8% year-over-year growth (up 12% organically), both resulting from favorable order timings. This includes accelerated customer stocking orders related to the COVID-19 pandemic.
Of late, IDEXX has been steadily expanding the test menu with CAG. A notable launch of recent times includes Catalyst Bile Acids test along with latest updates to its SediVue Neural Network 5.0.
However, economic stagnation due to the coronavirus outbreak is concerning. Meanwhile, the majority of IDEXX’s consolidated revenues is derived from the sale of products in international markets. Thus, the strengthening of the U.S. dollar’s exchange rate, relative to other currencies, left a negative impact on revenues derived in currencies other than the U.S. dollar as well as on profits drawn from products manufactured in the United States and sold internationally.
Key Picks
Some better-ranked stocks from the broader medical space are Quest Diagnostics Incorporated (DGX - Free Report) , Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp and QIAGEN N.V. (QGEN - Free Report) .
Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
LabCorp’s long-term earnings growth rate is estimated at 6.1%. The company presently has a Zacks Rank #2 (Buy).
QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>